PROTECTing Renal Transplant Recipients From Uncontrolled Gout
In the phase IV open-label PROTECT trial of pegloticase therapy (pegylated recombinant uricase) in treating severe gout in renal transplant recipients, 89% of patients achieved the primary endpoint of serum uric acid (sUA) less...
Read More